MarketMoodz
Seres Pauses SER-155 Study, Cuts Jobs to Extend Cash Runway into 2026
Seres Therapeutics paused further investment in the Phase 2 SER-155 study in allo-HSCT patients while seeking funding, and is cutting staff to conserve cash. The company also reaffirmed an early Q2 2026 readout for an Investigator-sponsored SER-155 trial as it pivots to a leaner, higher-priority pipeline.
Key Takeaways
- Seres pauses the SER-155 Phase 2 program while pursuing funding.
- Workforce reduction of about 30% to extend cash runway through Q3 2026.
- Cash balance around $47.6 million, funding operations through Q3 2026 (vs. prior plan through Q2 2026).
- Readout of investigator-sponsored SER-155 irEC study expected in early Q2 2026.
- Strategic shift prioritizes SER-603 and potential collaborations to fund or de-risk the pipeline.
People Involved
- No specific individuals mentioned
Entities Involved
- Seres Therapeutics Inc. (NASDAQ: MCRB)Biotech company
MarketMoodz Analysis
For investors, the move tightens the funding trajectory. By pausing SER-155 Phase 2 and trimming staff, Seres buys time and lowers near-term burn, pushing cash runway to through Q3 2026 but raising execution risk around SER-155 milestones.
Biotech funding dynamics often favor cost discipline and partnership deals when capital is tight. Seres’ pivot toward earlier-stage programs like SER-603, coupled with ongoing collaboration discussions, mirrors a broader industry pattern aimed at de-risking pipelines through strategic collaborations rather than sole financing.
Watch for any collaboration announcements, new financing terms, and updates on the Q2 2026 irEC readout timing. The next catalysts will likely determine how quickly Seres can advance SER-603 and whether external funding materializes to support the broader portfolio.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial